{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T09:55:50Z","timestamp":1773309350077,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.ad.2024.02.030","type":"journal-article","created":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T03:12:35Z","timestamp":1709694755000},"page":"125-133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Real-world Safety and Efficacy of Risankizumab in Psoriatic Patients: A Multicenter, Retrospective, and Not-interventional Study"],"prefix":"10.1016","volume":"116","author":[{"given":"A.","family":"Martorell-Calatayud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Santos-Alarc\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Sahuquillo-Torralba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Rivera-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Belinch\u00f3n-Romero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Ruiz-Genao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Romero-Mat\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Ruiz-Villaverde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ferran-Farr\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Gallardo-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Almenara-Blasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.A.","family":"Suarez-Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1.","family":"Gonz\u00e1lez-Cantero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Mart\u00ednez-Lorenzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.M.","family":"Fern\u00e1ndez-Armenteros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"del Alc\u00e1zar-Viladomiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Garc\u00eda-Latasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Rocamora-Durant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ara-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Mateu-Puchades","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Llamas-Velasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Vilarrasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Velasco-Pastor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"De la Cueva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.M.","family":"Carrascosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Magdaleno-Tapial","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2024.02.030_bib0160","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(07)61128-3","article-title":"Pathogenesis and clinical features of psoriasis","volume":"370","author":"Griffiths","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ad.2024.02.030_bib0165","doi-asserted-by":"crossref","first-page":"m1590","DOI":"10.1136\/bmj.m1590","article-title":"National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.ad.2024.02.030_bib0170","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"issue":"Suppl. 2","key":"10.1016\/j.ad.2024.02.030_bib0175","article-title":"Psoriasis assessment tools in clinical trials","volume":"64","author":"Feldman","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"Suppl. 2","key":"10.1016\/j.ad.2024.02.030_bib0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/jdv.13542","article-title":"Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology","volume":"30","author":"Daud\u00e9n","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2024.02.030_bib0185","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000250839","article-title":"Severe psoriasis \u2013 oral therapy with a new retinoid","volume":"157","author":"Fredriksson","year":"1978","journal-title":"Dermatologica"},{"key":"10.1016\/j.ad.2024.02.030_bib0190","doi-asserted-by":"crossref","first-page":"851","DOI":"10.17219\/acem\/69804","article-title":"The reliability of three psoriasis assessment tools: psoriasis area and severity index, body surface area and physician global assessment","volume":"26","author":"Bo\u017cek","year":"2017","journal-title":"Adv Clin Exp Med"},{"key":"10.1016\/j.ad.2024.02.030_bib0195","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2024.02.030_bib0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40257-017-0328-3","article-title":"Choosing first-line biologic treatment for moderate-to-severe psoriasis: what does the evidence say?","volume":"19","author":"Amin","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.ad.2024.02.030_bib0205","first-page":"CD011535","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"5","author":"Sbidian","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ad.2024.02.030_bib0210","doi-asserted-by":"crossref","first-page":"158","DOI":"10.5114\/reum.2019.86426","article-title":"Risankizumab in the treatment of psoriasis \u2013 literature review","volume":"57","author":"Banaszczyk","year":"2019","journal-title":"Reumatologia"},{"key":"10.1016\/j.ad.2024.02.030_bib0215","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/14712598.2022.2012567","article-title":"Risankizumab in psoriasis: prior biologics failure does not impact on short-term effectiveness","volume":"22","author":"Rivera-D\u00edaz","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.ad.2024.02.030_bib0220","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ad.2024.02.030_bib0225","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1001\/jamadermatol.2020.0723","article-title":"Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial","volume":"156","author":"Blauvelt","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ad.2024.02.030_bib0230","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","article-title":"Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ad.2024.02.030_bib0235","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s13555-021-00556-2","article-title":"Risankizumab for the treatment of moderate-to-severe psoriasis: real-life multicenter experience from the Czech Republic","volume":"11","author":"Gkalpakiotis","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.ad.2024.02.030_bib0240","first-page":"e15489","article-title":"Risankizumab for the treatment of moderate-to-severe psoriasis: a multicenter, retrospective, 1 year real-life study","volume":"35","author":"Caldarola","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.ad.2024.02.030_bib0245","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaad.2022.06.438","article-title":"Real-world patient-reported outcomes with risankizumab in patients with moderate to severe psoriasis from the CorEvitas Psoriasis Registry","volume":"87","author":"Strober","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2024.02.030_bib0250","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.7573\/dic.2023-1-8","article-title":"Effectiveness of risankizumab in the treatment of palmoplantar psoriasis: a 52-week Italian real-life experience","volume":"12","author":"Caldarola","year":"2023","journal-title":"Drugs Context"},{"key":"10.1016\/j.ad.2024.02.030_bib0255","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.3390\/biomedicines11061769","article-title":"Risankizumab: daily practice experience of high need patients","volume":"11","author":"Brunasso","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.ad.2024.02.030_bib0315","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1111\/jdv.17656","article-title":"A 52-week update of a multicentre real-life experience on effectiveness and safety of risankizumab in psoriasis","volume":"36","author":"Hansel","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2024.02.030_bib0320","unstructured":"World Health Organization (WHO). Obesity. Available in: https:\/\/www.who.int\/health-topics\/obesity#tab=tab_1 [last accessed 07.12.23]."},{"key":"10.1016\/j.ad.2024.02.030_bib0325","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/1744666X.2017.1292137","article-title":"The role of IL 23 in the treatment of psoriasis","volume":"13","author":"Puig","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.ad.2024.02.030_bib0330","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ad.2024.02.030_bib0335","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1080\/14712598.2022.2113872","article-title":"New frontiers in personalized medicine in psoriasis","volume":"22","author":"Camela","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.ad.2024.02.030_bib0340","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1046\/j.1468-3083.2001.00191.x","article-title":"Prevalence of psoriasis in Spain (Epiderma Project: phase I)","volume":"15","author":"Ferr\u00e1ndiz","year":"2001","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2024.02.030_bib0345","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.ad.2013.12.008","article-title":"Prevalence of psoriasis in Spain in the age of biologics","volume":"105","author":"Ferr\u00e1ndiz","year":"2014","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2024.02.030_bib0350","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1111\/jdv.17003","article-title":"A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic","volume":"35","author":"Hansel","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2024.02.030_bib0355","doi-asserted-by":"crossref","first-page":"adv00605","DOI":"10.2340\/actadv.v101.283","article-title":"Real-life effectiveness and safety of risankizumab in moderate-to-severe plaque psoriasis: a 40-week multicentric retrospective study","volume":"101","author":"Borroni","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ad.2024.02.030_bib0360","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.3390\/jcm12093233","article-title":"Long-term efficacy and safety of risankizumab for moderate to severe psoriasis: a 2-year real-life retrospective study","volume":"12","author":"Megna","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.ad.2024.02.030_bib0310","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1007\/s40744-022-00474-5","article-title":"Long-term efficacy and safety of risankizumab in patients with active psoriatic arthritis: results from a 76-week phase 2 randomized trial","volume":"9","author":"Mease","year":"2022","journal-title":"Rheumatol Ther"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000173102400187X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000173102400187X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T09:19:59Z","timestamp":1738401599000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000173102400187X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S000173102400187X"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2024.02.030","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world Safety and Efficacy of Risankizumab in Psoriatic Patients: A Multicenter, Retrospective, and Not-interventional Study","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2024.02.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 AEDV. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}